New Approaches to De-risking Early Drug Development
Summary: The biopharma industry as a whole is spending more money than ever on drug R&D, but the payback on productivity keeps shrinking. On a long-term basis, that’s unsustainable for the industry and has to change. EndPoints spoke with several of the leading experts in clinical trial design and drug development to see what they’re doing to pick the right candidates for clinical development and how they’re revamping projects to achieve approvals as efficiently as possible. Learn the opinion of experts from Merck, Sanofi, Catalent, Takeda, and J&J about their efforts to improve R&D efficiency.